Halberd (Halberd) EV-to-Revenue : (As of May. 21, 2024)

View and export this data going back to 2009. Start your Free Trial

What is Halberd EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Halberd's enterprise value is $0.38 Mil. Halberd does not have enough years/quarters to calculate its Revenue for the trailing twelve months (TTM) ended in Jul. 2023. Therefore, GuruFocus does not calculate Halberd's EV-to-Revenue at this moment.

The historical rank and industry rank for Halberd's EV-to-Revenue or its related term are showing as below:

HALB' s EV-to-Revenue Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0
Current: 125.67

HALB's EV-to-Revenue is ranked worse than
85.81% of 1043 companies
in the Biotechnology industry
Industry Median: 8.21 vs HALB: 125.67

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-21), Halberd's stock price is $0.0088. Halberd does not have enough years/quarters to calculate its Revenue per Share for the trailing twelve months (TTM) ended in Jul. 2023. Therefore, GuruFocus does not calculate Halberd's PS Ratio at this moment.

Halberd EV-to-Revenue Historical Data

The historical data trend for Halberd's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd EV-to-Revenue Chart

Halberd Annual Data

Trend

Jul08

Jul22

Jul23

EV-to-Revenue

818.22

1,784.65

Halberd Semi-Annual Data
	Jul08	Jul22	Jul23
EV-to-Revenue	-	818.22	1,784.65

Competitive Comparison of Halberd's EV-to-Revenue

For the Biotechnology subindustry, Halberd's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Halberd's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halberd's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Halberd's EV-to-Revenue falls into.

Halberd EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Halberd's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	0.377	/
	=

Halberd (OTCPK:HALB) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Halberd's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.0088	/
	=

Halberd EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Halberd's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Halberd (Halberd) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 25, Jackson Center, PA, USA, 16133

Website

https://www.halberdcorporation.com

Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.

Executives

John Christopher Maddox	director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO	10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist	director, 10 percent owner, officer: CEO, Secretary and Director	24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr.	director	50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas	director	280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236